Q: Could you summarize the key efficacy findings from the OrigAMI-4 trial, particularly response rates, duration of response, and progression-free survival, in this heavily pretreated population with head and neck squamous cell carcinoma?
Kevin…
Amivantamab Shows 45% Response Rate in Pretreated Head and Neck Cancer: OrigAMI-4 Findings
